Innovent Biologics: Billion-Dollar Deal with Eli Lilly Finalized
Reading Time: 3 minutes
The new partnership involves the joint development of new medications by both companies. This marks already the seventh joint project of the two pharmaceutical giants. The Chinese pharmaceutical company Innovent Biologics is solidifying its alliance with the US giant Eli Lilly . Together, they aim to develop new therapies that could trigger milestone payments of an astronomical 8.5 billion USD. An 8.5 billion USD promise for cancer therapy Innovent announced on Sunday that the company and its subsidiaries have signed...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
